GlycoNex (ROCO:4168) Current Accrued Expense : NT$0.00 Mil (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Current Accrued Expense?

GlycoNex's Current Accrued Expense for the quarter that ended in Mar. 2024 was NT$0.00 Mil.

GlycoNex Current Accrued Expense Historical Data

The historical data trend for GlycoNex's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Current Accrued Expense Chart

GlycoNex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

GlycoNex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

GlycoNex Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

GlycoNex Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of GlycoNex's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoNex (ROCO:4168) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221

Website

http://www.glyconex.com.tw

GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines